Skip to content

MRI-guided rTMS and tDCS, alone or combined, for auditory hallucinations in schizophrenia: a randomized pre-post controlled study

MRI-guided rTMS and tDCS, alone or combined, for auditory hallucinations in schizophrenia: a randomized pre-post controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600120334
Enrollment
Unknown
Registered
2026-03-12
Start date
2026-03-19
Completion date
Unknown
Last updated
2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia with auditory hallucinations

Interventions

rTMS-alone group:rTMS
tDCS-alone group:tDCS
Combined rTMS+tDCS group:rTMS+tDCS

Sponsors

The First Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1.Diagnosis of schizophrenia according to the International Classification of Diseases, 10th Revision (ICD-10); 2.Age between 18 and 55 years, with a disease duration of >= 2 years and stable medication dosage for at least one month; 3. Persistent auditory hallucinations lasting for >= 6 months; 4. Receiving antipsychotic medication at a stable dose for at least 4 weeks but still exhibiting treatment-resistant AVH (defined as an Auditory Hallucination Rating Scale [AHRS] score >= 4, indicating at least moderate severity); 5. Written informed consent obtained from the patient and/or their legal guardian.

Exclusion criteria

Exclusion criteria: 1.Presence of severe or unstable organic diseases, acute brain injury, or infection; 2.Skin lesions or impaired integrity at the electrode placement sites, or known allergy to electrode gel or adhesive materials; 3. A score = 3 on the suicide item of the 17-item Hamilton Depression Rating Scale (HAMD-17); 4. Concurrent participation in another clinical trial; 5. Prior exposure to any neurostimulation therapy (including electroconvulsive therapy, rTMS, tDCS, or transcranial alternating current stimulation) within the past three months; 6. Presence of any implanted medical or metallic device (such as a cochlear implant, cardiac pacemaker, deep brain stimulator, or intracranial metal); 7. Any other condition deemed by the investigators to make the participant unsuitable for the study.

Design outcomes

Primary

MeasureTime frame
Anxiety ;The degree of alleviation of auditory hallucinations;The functional connectivity strength between the temporoparietal junction (TPJ) and the dorsolateral prefrontal cortex (DLPFC);The degree of remission of schizophrenia;

Secondary

MeasureTime frame
Depression;

Countries

China

Contacts

Public ContactLi Xiao

The First Affiliated Hospital of Chongqing Medical University

lixiao@hospital.cqmu.edu.cn+86 185 2381 0102

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 20, 2026